Miyano [4] | Gastric adenocarcinoma | TBB and SLB | NR | Yes | Yes (S-1) | No | >9 months |
Kayatani [5] | Adenocarcinoma of unknown origin | SLB | “Normal”# | No | Yes (S-1 and cisplatin, S-1 and gemcitabine) | No | 15 months |
Kitamura [6] | Breast adenocarcinoma | TBB | 41# | Yes | Yes (irinotecan, S-1) | No | 3 months |
Ogawa [2] | Gastric and duodenal adenocarcinoma | TBB | (48)¶ | No | Yes (TS-1) | Imatinib (100 mg·day−1) | 12 months |
Higo [7] | Colic adenocarcinoma | Swan–Ganz (capillary blood) | 77/31 (48)¶ | No | Yes (S-1, bevacizumab) | Imatinib (50–200 mg·day−1) | 12 months |
Fukada [8] | Breast adenocarcinoma | Swan–Ganz (capillary blood) | 93/39 (60) | No | No | Imatinib (50–400 mg·day−1) | 56 days |
Minatsuki [9] | Gastric adenocarcinoma | SLB | (48)¶ | No | Yes (S-1) | Imatinib (200 mg·day−1) | 12 months |